Chronic Lymphocytic Leukemia | Specialty

The chronic lymphocytic leukemia condition center is a comprehensive resource for clinical news on chronic lymphocytic leukemia. Read more at OncLive.

Zanubrutinib Demonstrates Long-Term Efficacy, Safety in Relapsed/Refractory CLL/SLL

December 7th 2025

Zanubrutinib displayed long-term PFS and responses in patients with relapsed/refractory CLL/SLL.

Pirtobrutinib Matches Ibrutinib in ORR, Shows Potential PFS Edge in BTK Inhibitor–Naive CLL/SLL

December 7th 2025

Pirtobrutinib yeilds superior overall response rates and promising progression-free survival compared to ibrutinib in chronic lymphocytic leukemia.

Lisaftoclax Displays Activity in R/R CLL/SLL

December 6th 2025

Lisaftoclax demonstrated efficacy and safety for the treatment of patients with relapsed/refractory CLL/SLL.

BGB-16673 Is Safe, Highly Active Regardless of Baseline Mutations or High-Risk Features in R/R CLL/SLL

December 6th 2025

In the CaDAnCe-101 study, BGB-16673 was tolerable, effective, and showed sustained disease control in high-risk, heavily pretreated, relapsed/refractory CLL/SLL.

Venetoclax-Based, Fixed-Duration Regimens Match Continuous Ibrutinib in Frontline CLL

December 6th 2025

Fixed-duration venetoclax combinations delivered PFS comparable with continuous ibrutinib in the phase 3 CLL17 trial.

Inside the Most Anticipated CLL Abstracts: What to Expect From ASH 2025

December 5th 2025

Ahead of the 2025 ASH Annual Meeting, OncLive spoke with experts in CLL care to preview the most anticipated meeting abstracts.

FDA Approves Pirtobrutinib for Relapsed or Refractory CLL/SLL

December 3rd 2025

The FDA has granted traditional approval to pirtobrutinib for covalent BTK inhibitor–exposed, relapsed/refractory CLL or SLL.

Experts Unpack the Most Notable NCCN Guideline Changes Heading Into 2026

December 1st 2025

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.

BTK Inhibitors, CAR T-Cell Therapies, and JAK Inhibitors Refine Hematologic Oncology Standards

October 21st 2025

Aaron Gerds, MD, MS, discusses the role of BTK inhibitors in CLL, real-world data with CAR T-cell therapies in LBCL, and JAK inhibitors for myelofibrosis.

Baseline Cardiovascular Assessment, Monitoring Are Crucial With BTK Inhibitors in CLL and Other Hematologic Malignancies

October 14th 2025

A meta analysis found BTK inhibitors carry risks of hypertension, atrial fibrillation, and hemorrhage, underscoring the need for cardiovascular monitoring.

Removal of REMS Requirements Could Help Streamline CAR T-Cell Therapy Access in Hematologic Cancer Care

October 10th 2025

The removal of REMS programs for approved CAR T-cell therapies could enable improved access and streamlined management of hematologic malignancies.

Retrospective Study Shows BTK Inhibitors Provide PFS Advantage in NOTCH1-Mutated CLL

October 6th 2025

BTK inhibitor therapy improved PFS vs chemoimmunotherapy in NOTCH1-mutated CLL, highlighting the value of NOTCH1 screening to guide treatment selection.

Dr Visentin on the Relevance of Cost Analysis in Guiding Treatment Sequencing for CLL

October 3rd 2025

Andrea Visentin, MD, discusses the relevance of cost analysis in guiding treatment sequencing for patients with chronic lymphocytic leukemia.

Dr Khan on the Evolution of BTK Inhibitors in CLL

October 1st 2025

Cyrus M. Khan, MD, discusses how ibrutinib—a first-generation BTK inhibitor—compares with second-generation BTK inhibitors in CLL.

FDA Grants Fast Track Designation to UB-VV111 for R/R B-Cell Malignancies

September 30th 2025

The in vivo CAR T-cell therapy UB-VV111 has received fast track designation from the FDA for the management of relapsed/refractory LBCL and CLL.

Driving Outcomes in CLL: Treatment Sequencing Strategies

September 29th 2025

Workshop faculty shared insights on first-line, R/R, and post-BTKi CLL care, plus sequencing, shared decision-making, and emerging therapies.

Dr Ghia on the Implications of Data From CAPTIVATE for Fixed-Duration Ibrutinib Plus Venetoclax in CLL/SLL

September 26th 2025

Paolo Ghia, MD, provided insights into the significance of updated data from the final analysis of the phase 2 CAPTIVATE study in CLL/SLL.

Dr Khan on Key BTK Inhibitor Updates in Relapsed/Refractory CLL

September 26th 2025

Cyrus M. Khan, MD, discusses the key BTK inhibitor updates for the treatment of patients with relapsed/refractory CLL from the 2025 ASCO Annual Meeting.

Zanubrutinib Shows Superior PFS vs Venetoclax/Obinutuzumab in Indirect Comparison of Treatment-Naive CLL

September 25th 2025

An indirect comparison of SEQUOIA and CLL14 shows zanubrutinib improved PFS over venetoclax/obinutuzumab in treatment-naive CLL after baseline adjustment.

Dr Ghia on Safety Considerations After Fixed-Duration Ibrutinib Plus Venetoclax in CLL

September 18th 2025

Paolo Ghia, MD, PhD, discusses the safety considerations of fixed-duration ibrutinib plus venetoclax after retreatment in patients with CLL.